Cargando…

Anti-HER2/Neu passive-aggressive immunotherapy

Preclinical studies have established that CD8(+) T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER2/Neu the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mortenson, Eric D, Fu, Yang-Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935925/ https://www.ncbi.nlm.nih.gov/pubmed/24605268 http://dx.doi.org/10.4161/onci.27296

Ejemplares similares

Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2021)

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy
por: Lazear, Eric, et al.
Publicado: (2017)

AEG-1–AKT2: A novel complex controlling the aggressiveness of glioblastoma
por: Emdad, Luni, et al.
Publicado: (2015)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications
por: Compte, Marta, et al.
Publicado: (2014)

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

Immunotherapy of HPV-associated head and neck cancer: Critical parameters
por: Nizard, Mevyn, et al.
Publicado: (2013)

Pharmacological DNA demethylation: Implications for cancer immunotherapy
por: Roulois, David, et al.
Publicado: (2015)

A novel pathway links telomeres to NK-cell activity: Implications for immunotherapy
por: Cherfils-Vicini, Julien, et al.
Publicado: (2014)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Shock block for improved immunotherapy
por: Rao, Aparna, et al.
Publicado: (2012)

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers
por: Lebret, Thierry, et al.
Publicado: (2015)

Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
por: Fisher, Jonathan, et al.
Publicado: (2014)

Engineering Grp170-based immune modulators for cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2013)

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Personalizing immunotherapy: Balancing predictability and precision
por: Agur, Zvia, et al.
Publicado: (2012)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance
por: Ikink, Gerjon J., et al.
Publicado: (2017)

IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Chemokine-enhanced DNA vaccination in cancer immunotherapy
por: Igoucheva, Olga, et al.
Publicado: (2013)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
por: Deng, Liufu, et al.
Publicado: (2014)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
por: Kim, Peter S, et al.
Publicado: (2014)

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy
por: Mikucki, Maryann E., et al.
Publicado: (2016)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

The immune landscape of human tumors: Implications for cancer immunotherapy
por: Bindea, Gabriela, et al.
Publicado: (2014)

FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012)

New insights into the role of NK cells in cancer immunotherapy
por: Salagianni, Maria, et al.
Publicado: (2012)

DKK1 as a novel target for myeloma immunotherapy
por: Qian, Jianfei, et al.
Publicado: (2012)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

Cancer immunotherapy with exosomes requires B-cell activation
por: Näslund, Tanja I, et al.
Publicado: (2013)

Modifying tumor-associated macrophages: An important adjunct to immunotherapy
por: Fridlender, Zvi G, et al.
Publicado: (2013)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Immunotherapy of acute myeloid leukemia based on γδ T cells
por: Gertner-Dardenne, Julie, et al.
Publicado: (2012)

Targeting dendritic cells in situ for breast cancer immunotherapy
por: Wang, Bei
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t6ao5dp9c8vdaunhr1n1cgj9gd